The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice  by Ivanovski, Ognen et al.
Kidney International, Vol. 67 (2005), pp. 2288–2294
VASCULAR BIOLOGY – HEMODYNAMICS – HYPERTENSION
The antioxidant N-acetylcysteine prevents accelerated
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OGNEN IVANOVSKI, DOROTA SZUMILAK, THAO NGUYEN-KHOA, NADYA RUELLAN, OLIVIER PHAN,
BERNARD LACOUR, BE´ATRICE DESCAMPS-LATSCHA, TILMAN B. DRU¨EKE, and ZIAD A. MASSY
INSERM Unit 507, Necker Hospital, Paris, France; Laboratory of Biochemistry A, Necker Hospital, Paris, France; Divisions of
Clinical Pharmacology and Nephrology, University of Picardie and Amiens University Hospital, Amiens, France
The antioxidant N-acetylcysteine prevents accelerated
atherosclerosis in uremic apolipoprotein E knockout mice.
Background. Cardiovascular disease is the most frequent
cause of mortality in chronic renal failure (CRF). Therefore, it
is important to identify appropriate treatment measures. The
antioxidant N-acetylcysteine (NAC) has been shown to re-
duce cardiovascular events in hemodialysis patients. Here we
examine a possible direct effect of NAC supplementation on
uremia-enhanced atherosclerosis in apolipoprotein E–deficient
(apoE−/−) mice.
Methods. Uremia was induced surgically in 8-week-old fe-
male apoE−/− mice. Two weeks after creation of CRF mice were
randomized to receive either NAC (daily oral gavage with 200
mg/kg for 8 weeks) or placebo. They were compared to a control
group of sham-operated apoE−/− mice receiving placebo. After
8 weeks of treatment, the mice were sacrificed, and the cross-
section surface area of atherosclerotic plaques was measured in
aortic root and descending aorta.
Results. At 10 weeks following surgery, atherosclerotic le-
sions were significantly larger in uremic apoE−/− mice than in
nonuremic controls. This accelerated atherosclerosis was asso-
ciated with an increase in aortic nitrotyrosine expression and
collagen plaque content. NAC treatment inhibited the pro-
gression of atherosclerotic lesions and plaque collagen content
compared with placebo treatment. In addition, plaques from
NAC-treated uremic animals showed a significant decrease in
nitrotyrosine expression whereas the degree of macrophage in-
filtration was comparable in both uremic groups. There was no
difference in mean arterial blood pressure between the three
groups.
Conclusion. We show for the first time that the antioxidant
NAC is capable of reducing atheroma progression, in an ani-
mal model of uremia-enhanced atherosclerosis, probably via a
decrease in oxidative stress.
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Chronic renal failure (CRF) patients are at greater risk
of developing atherosclerosis than patients with normal
kidney function [1]. Consequently, the mortality rate in
such patients is substantially higher than in the general
population, and deaths are mainly attributable to cardio-
vascular disease [2, 3]. Advanced age, dyslipidemia, hy-
pertension, glucose intolerance, and cigarette smoking,
which are well-known causes in the general population,
only partly explain the increased incidence of cardiovas-
cular complications. Uremic patients are exposed to a
number of additional factors. Thus, they suffer from a
dysregulation of the immune system and exhibit an ex-
cessive generation of reactive oxygen species (ROS). In-
creased oxidative stress induced by ROS is associated
with atherosclerosis and cardiovascular morbidity and
mortality in general population and in CRF patients [4,
5]. Therefore, antioxidant administration appears to be
promising approach. However, a causal relationship be-
tween oxidative stress and cardiovascular disease has not
yet been firmly established in CRF patients [5]. Published
data are limited with respect to the possible success of in-
terventional trials with antioxidants aimed at reducing
cardiovascular disease in these patients [6, 7].
Recently, independent results from three research
groups provided evidence that nephrectomy-induced
uremia accelerated atherosclerosis in apolipoprotein E-
deficient (apoE−/−) mice [8–10]. This new uremic mouse
model provides a useful tool to analyze different cellular
and molecular mechanisms underlying atherosclerosis in
the settings of CRF and to test possible new therapeu-
tic strategies. The finding of increased aorta nitrotyrosine
expression in uremic apoE−/− mice [9, 10] points to en-
hanced oxidative stress. However, the exact mechanisms
underlying the accelerated progression of atherosclerotic
lesions in uremic arteries remain to be clarified.
N-acetylcysteine (NAC), a thiol-containing antiox-
idant, is currently used therapeutically in several
disorders related to oxidative stress such as chronic bron-
chitis and acetaminophen poisoning. It has also been
shown to protect renal function in patients with acute
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and CRF [11, 12]. NAC exerts direct and indirect antiox-
idant activity due to its sulfhydryl group [13, 14]. More-
over, NAC releases cysteine after deacetylation, which
in turn increases the formation of reduced glutathione
sulfhydryl (GSH) within the intracellular pool of antiox-
idant molecules [15]. GSH in turn can react with perox-
ynitrite to form S-nitrosothiols, which may prevent the
accumulation of peroxynitrite toward the range of toxic
levels and protect against nitrosative stress [16]. GSH
represents one of the most important natural antioxi-
dant defense systems that decrease early in the course
of CRF and progresses with its degree of severity [17].
NAC successfully reduces plasma malondialdehyde lev-
els [18] and homocysteine concentration [19], and im-
proves pulse pressure and endothelial function in CRF
patients [19]. Finally, NAC has been recently shown to
reduce cardiovascular events in chronic hemodialysis pa-
tients [7]. However, whether this positive effect was re-
lated to a direct action of NAC on atherosclerosis pro-
gression is unknown.
The present study was designed to test the hypothesis
that chronic attenuation of oxidative stress by NAC has
a direct impact on uremia-enchanced atherosclerosis in
apoE−/− mice
METHODS
Animals
Experiments were performed in female apoE−/− mice,
which were obtained from Charles Rivers Breeding Lab-
oratories (Wilmington, MA, USA) and then bred at the
Necker medical faculty (Paris, France). All mice were
backcrossed for 10 generations to the C57BL/6J genetic
background. The mice were housed in polycarbonate
cages in pathogen-free, temperature-controlled (25◦C)
facility, with a strict 12-hour light-dark cycle, and were
given free access to water and standard chow diet (Har-
lan Teklad Global Diets, Gannat, France). The compo-
nents of the diet as listed by the manufacturer were 5.7%
fat, 18.9% protein, 72.3% carbohydrates, 1.01% calcium,
0.65% phosphorus, 0.2% magnesium, and 1540 IU/kg vi-
tamin D3. After sexual maturation at 4 weeks of age, the
mice were separated by gender and housed in groups up
to five.
Creation of uremia
Uremia was induced by a two-step surgical procedure
according to Gagnon and Ansari [20], as previously de-
scribed [8]. Briefly, at age of 8 weeks, the right kidney was
exposed and electrocoagulation of the entire surface was
performed except for a 2 mm of intact tissue around the
hilum. Special care was taken not to manipulate with the
ureter and to preserve the suprarenal gland. At 10 weeks
of age, left kidney was removed after double ligation of
the renal blood vessels and the ureter. Control animals
underwent sham operatation, that is, both kidneys were
decapsulated. All surgical procedures were done under
ketamine/xylazine anesthesia (100 mg/kg and 20 mg/kg)
and 5-0 silk sutures were used throughout.
Experimental protocol
Blood samples were taken 2 weeks after nephrectomy
and animals from the uremia group with a serum urea
level > 20 mmol/L (normal urea level 8 to 10 mmol/L)
were randomized to two subgroups: subgroup 1 was
treated with NAC (Zambon Group, Milan, Italy),
whereas subgroup 2 received placebo. NAC was dissolved
in distilled water and administered daily by oral gavage
at a dose of 200 mg/kg for 8 weeks. NAC dosage was de-
termined according to previous reports of NAC adminis-
tration to nonuremic mice [21]. Control animals received
distilled water only.
Biochemical analysis
Blood samples were obtained from mice at baseline
and then at monthly intervals until the end of the study.
Serum urea, total cholesterol, and triglycerides were mea-
sured using Hitachi 917 autoanalyzer (Roche, Meylan,
France). Plasma urea is a more sensitive marker of uremia
than creatinine in mice, as the picric acid analysis (Jaffe´
method) tends to overestimate creatinine levels due to
the presence of interfering substances [22]. Urine was
taken prior to sacrifice and urinary protein and creatinine
concentration was measured as previously described [23].
Preparation of the aortic sinus
Each mouse was anesthetized and whole blood was
collected via cardiac puncture. The aortic tree was per-
fused with 20 mL phosphate-buffered saline (PBS) via
26 G cannula inserted in the left ventricle, allowing un-
restricted reflux from an incision into the right atrium.
To further minimize possible adhesion of contaminating
nonarterial cells to the arterial wall, adjacent lung tis-
sue was removed from the exterior of the aorta prior to
perfusion.
The following procedure of organ dissection and prepa-
ration was done as reported previously [8].
Preparation of the descending aorta
The aorta and its main branches were dissected from
the left subclavian artery to the iliac bifurcation. The ad-
ventitia was removed as much as possible in situ to pre-
vent misinterpretation resulting from Sudan staining of
the vessel. The aorta was cut in two (thoracic and ab-
dominal part) using the level of the diaphragm as cut-
ting point. The remaining branches were then cut off and
the aorta (from the heart to approximately 5 mm be-
yond the iliac bifurcation) was removed and fixed with
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4% paraformaldehyde for further investigations. After a
minimum of 24 hours for initial fixation the aortas were
opened longitudinally. The primary incision followed the
inner side of the thoracic part and the inner curvature of
the arch. To obtain a flat preparation for imaging, a sec-
ond incision was made along the outer curvature of the
arch. The aortas were then stained with Oil red O and
a third “cleaning” was performed, by carefully dissect-
ing the remaining adventitial tissues from the outer wall
of the aorta. All procedures were made under dissecting
microscope.
Quantification of atherosclerotic lesions
Serial 10 lm sections of the aortic sinus with valves (60
to 80 per mouse) were cut in a cryostat starting from the
appearance of the first valve (point zero). Of every tenth
sections, one was kept for detection of lipid deposition
and stained with Oil red O, while remaining sections were
used for other staining and immunocytochemistry anal-
yses. The Oil red O stained cryosections (slide 1) were
quantified at 2.5 × magnification. The image was cap-
tured on a microcomputer equipped with Histolab soft-
ware (Microvision Instruments, Evry, France) and ana-
lyzed by computerized image analysis.
Evaluation of the atherosclerotic plaque area of the
entire aorta opened longitudinally was made by the “en
face” method [24] using the same image analysis system.
The extent of atherosclerosis was expressed as the percent
of surface area of the entire aorta covered by lesions.
The acquisition of images and analysis of lesions were
performed in blinded fashion.
Quantification of monocyte-macrophage (MOMA)
infiltration, collagen content, and nitrotyrosine
expression in aortic lesions
MOMA infiltration and collagen content were quanti-
fied as reported previously [8].
For nitrotyrosine analysis aortic sections were first
fixed in room temperature acetone for 10 minutes and
placed in bath of wash buffer. The sections were then
preincubated in peroxidase blocking solution (Dako
Cytomation, Trappes, France) for 5 minutes before incu-
bation for 15 minutes at room temperature with biotiny-
lated nitrotyrosine monoclonal mouse antibody (Cay-
man Chemical, SpiBio, Massy, France). Antibodies were
used in diluents with background reducing components
(Dako). After repeat rinsing with Tris buffer, the sec-
tions were treated with peroxidase-labeled streptavidin
(Dako) for 15 minutes followed by reaction with di-
aminobenzidine/hydrogen peroxidase as chromogen sub-
strate which results in a brown-colored precipitate at the
antigen site. Positive controls were obtained by pretreat-
ing the sections with peroxynitrite generated in situ with
mixture solution (vol/vol) of sodium nitrite (1 mmol/L)
and hydrogen peroxide (1 mmol/L). Negative controls in-
cluded omission of the primary antibody. At the end, the
sections were counterstained with hematoxylin.
Blood pressure measurements
We measured mean arterial blood pressure at the day of
sacrifice using direct intra-arterial recording as previously
described [8].
Statistical analysis
Data were analyzed by analysis of variance (ANOVA),
chi-square, linear regression analyses, and Student un-
paired t tests, as appropriate. Results were expressed as
means ± SEM. Differences between groups were consid-
ered significant when P < 0.05.
RESULTS
Body weight and serum biochemistry
Body weight was comparable for the three study groups
(Table 1). Compared to the nonuremic control group, ure-
mic placebo group showed a significant increase in serum
urea, total cholesterol, and triglycerides (Fig. 1). Such an
increase was also observed in uremic apoE−/− mice re-
ceiving NAC treatment (Fig. 1). No significant difference
in serum urea or lipid levels was found between NAC- and
placebo-treated uremic mice. Urinary protein/creatinine
ratio excretion was comparable between the three groups
(Table 1). Similarly, mean arterial blood pressure did not
differ (Table 1).
Atheromatous lesions of aorta
Mice of uremic placebo group showed a significant in-
crease in atherosclerotic surface area in the aortic sinus
compared with the sham operated control group (Figs. 2A
and 3A). Likewise, total aortic plaque area fraction in de-
scending aorta was markedly larger in uremic compared
with control mice. Evaluation of specific areas within the
aorta indicated that this increase in atherosclerosis was
observed in uremic animals in both thoracic (Figs. 2B and
3B) and abdominal aortic regions (data not shown). NAC
treatment of uremic mice led to a significant reduction of
the lesion surface area in the aortic root, as compared to
placebo-treated uremic mice (Figs. 2A and 3A). In line
with the aortic root findings, treatment with NAC also
resulted in a significant reduction of lesion surface area
in both thoracic aorta (Figs. 2B and 3B) and abdominal
aorta (data not shown). There were no significant correla-
tion between serum urea or cholesterol levels on the one
hand and the atherosclerotic plaque area on the other
hand.
Ivanovski et al: Atherosclerosis and antioxidants in uremic mice 2291
Table 1. Characteristics of the mice at the end of the study
Control Uremic Uremic + N-acetylcysteine
(N = 9) (N = 10) (N = 11)
Body weight g 22.9 ± 0.3 21.8 ± 0.6 22.6 ± 0.3
Mean arterial pressure mm Hga 67.5 73.7 68.7
Macrophage infiltration% of lesions 15.0 ± 3.4 18.2 ± 2.5 13.1 ± 1.6
Collagen content% of lesions 22.4 ± 2.9 36.9 ± 2.1b,c 26.7 ± 2.4
Nitrotyrosine expression% of animals 12.5 87.5d 27.3
Protein/creatinine ratio g/mmol/L 0.37 ± 0.04 0.35 ± 0.05 0.37 ± 0.15
Values are means ± SEM.
aN = 4 for the three groups; bP < 0.01 vs. control group; cP < 0.05 vs. uremic + N-acetylcysteine group; dP < 0.02 vs. control group or uremic + N-acetylcysteine
group
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Fig. 1. Serum concentrations of urea (A), to-
tal cholesterol (B), and triglycerides (C) on
the day of nephrectomy before introducing
N-acetylcysteine (NAC) treatment and on
the day of sacrifice (10 weeks later). Note
that only two groups of mice existed at time
of nephrectomy (sham and electrocoagulated
mice, respectively), that is, before randomiza-
tion to the three treatment groups. Number of
animals as shown in Table 1 except for tryg-
lycerides (N = 5) for the three groups. Nx is
left total nephrectomy. P < 0.01 analysis of
variance (ANOVA) between groups at sacri-
fice ∗P < 0.01 Fischer’s post hoc least signifi-
cant difference (PLDS) test between chronic
renal failure (CRF) and control mice at sacri-
fice Values are means ± SEM.
Total collagen content, nitrotyrosine, and MOMA
infiltration
To investigate whether NAC had any impact on plaque
composition in uremic mice, detailed histologic studies
analyzing lesion nitrotyrosine expression, macrophage
infiltration, and collagen content were performed. Col-
lagen content was increased in the lesions of uremic
apoE−/− mice as compared to control animals (Table 1)
(Fig. 4A and B). NAC treatment significantly reduced
collagen content to levels that were similar to the ones
observed in control animals (Table 1) (Fig. 4C). Further-
more, uremic mice showed an incease in nitrotyrosine ex-
pression in the aorta compared to nonuremic control mice
(Table 1) (Fig. 4D and E). Such an increase was observed
in the atherosclerotic plaques and also in the aortic me-
dial layer in the uremic animals (data not shown). NAC
treatment in uremic mice significantly prevented the ob-
served up-regulation (Table 1) (Fig. 4F). The percentage
of lesion cross-section area occupied by macrophages, as
revealed by MOMA-2 staining, was comparable between
the three groups (Table 1).
DISCUSSION
In the present study, we showed that the administration
of the antioxidant NAC led to a reduction of atheroma-
tous lesion progression in an animal model of uremia-
enhanced atherosclerosis. This reduction was associated
with a decrease of plaque collagen content and aortic
nitrotyrosine expression, but not with macrophage infil-
tration.
The induction of uremia in apoE−/− mice actually led to
significant plaque progression in all aortic segments stud-
ied, and this enhancement could be prevented by NAC
treatment. Our finding could serve as a pathogenetic ex-
planation for the recent observation by Tepel et al [7] who
showed that chronic dialysis patients given a NAC sup-
plement for 141/2 months had a better outcome in terms
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Fig. 2. Effect of 8-week N-acetylcysteine (NAC) treatment vs. placebo
on atherosclerotic plaque surface area in aortic root (A) and thoracic
aorta (B) in female uremic apolipoprotein E-deficient (apo E−/−) mice.
NAC prevented uremia-accelerated atherosclerosis in both aortic re-
gions. Control placebo (N = 8), uremic placebo (N = 7), and uremic
NAC (N = 11). Values are means ± SEM
of combined cardiovascular events than placebo-treated
dialysis patients.
The beneficial effects of NAC in uremia-enhanced
atherosclerosis development might be explained by an
interference with oxidative stress. Evidence from reliable
oxidative stress markers present in the plasma of CRF pa-
tients indicates that CRF is a pro-oxidant state [4, 5]. The
results of the present study and previous studies by oth-
ers [9, 10] in uremic mouse models are in agreement with
this hypothesis. Oxidative damage to endothelial cells is
postulated to be of prime importance in the development
of fatty streaks, the early lesion of atherosclerosis [25]. In
the present setting, the NAC effect was associated with
decreased nitrotyrosine expression in the aorta of ure-
mic mice. This finding further supports the hypothesis
linking oxidative stress and atherosclerosis in CRF, and
points to the possible importance of nitrosative-oxidative
stress in the accelerated atherosclerosis of CRF apoE−/−
mice. Nitrotyrosine is an indirect marker of peroxynitrite
generation that results from the reaction between nitric
oxide and superoxide. Peroxynitrite further sustains ox-
idative injury to the endothelium and reduces nitric oxide
availability. Nitrotyrosine has been shown to be present
in proteins in a variety of clinical conditions, including
atherosclerotic lesions in human coronary arteries, postis-
chemic heart, and placenta during preeclampsia [26–28].
NAC, by increasing the formation of GSH [15], can pro-
tect against nitrosative stress by favoring the reaction
between GSH and peroxynitrite to form S-nitrosothiols
[16]. Of note, GSH deficiency appears early in the course
of CRF and progresses with its degree of severity [17].
Additional effects of NAC include direct inactivation of
ROS and HOCl by conjugation or reduction, forming
NAC radicals [13]. However, the effects of NAC on chlo-
rinated stress is less likely to explain its atherosclerosis
protective effects in mice, since it has been shown that,
on the opposite, an increase myeloperoxidase-generated
reactive intermediates has a protective role in murine
atherosclerosis [29]. However, a possible protective vas-
cular action of NAC on chlorinated stress in CRF patients
cannot be excluded, and could certainly explain the bet-
ter cardiovascular outcome in terms of combined events
in the study of Tepel et al [7]. Indeed, in dialysis patients,
chlorinated stress appears to prevail since we and others
did not observe an increase of plasma nitrotyrosine lev-
els, whereas high concentrations of plasma chlorinated
markers were present [30, 31]. These observations are
in agreement with possible differences between murine
and human atherosclerosis development with regard to
the involvement of chlorinated stress.
The total serum cholesterol concentration was higher
in CRF mice than in controls. High cholesterol is a well-
identified risk factor in the atherosclerotic process and
surely contributed to the development of accelerated
atherosclerosis in our experimental model. However, in
the present study NAC treatment did not affect serum
cholesterol. Thus, it appears that mechanisms other than
a reduction of serum cholesterol were involved in the ob-
served antiatherosclerotic effect of NAC.
Increased production and deposition of extracelular
matrix proteins, including collagens, are a hallmark of fi-
brosis. Extracellular matrix collagen is the primary com-
ponent of atherosclerotic plaque structure. In the present
study the atheromatous lesions of uremic animals ex-
hibited a marked increase in collagen content although
there was no evidence of increased infiltration by inflam-
matory cells, which is in agreement with our previous
report [8]. NAC treatment significantly reduced the col-
lagen content, suggesting that oxidative stress may be
involved in uremia-stimulated collagen plaque produc-
tion. In line with this contention, Liu et al [32] showed
that NAC abrogated transforming growth factor (TGF)-
stimulated collagen production in fibroblasts. NAC also
blocked homocysteine-induced collagen expression in
human vascular smooth muscle cells [33]. Similarly, it
has been shown that treatment with the antioxidant
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Fig. 3. Representative findings of atherosclerosis progression in aortic
root and thoracic aorta in the three study groups. (A) Increased Red oil
O–positive lipid staining in aortic root of placebo-treated uremic mice,
compared with nonuremic control mice and N-acetylcysteine (NAC)-
treated uremic animals, respectively. (B) Red oil O–positive lipid stain-
ing in several different arterial and arteriolar ostia of the descending
thoracic aorta (arrows) and more diffuse wall deposits of the aortic wall
of placebo-treated uremic mice (arrowhead). No such lipid staining is
seen in control placebo and NAC-treated uremic mice, respectively.
alpha-tocopherol prevented myocardial fibrosis and car-
diomyocyte/capillary mismatch in rats with CRF [34].
There are certain limitations to the interpretation
of the present study. No animal model mimics human
atherosclerosis perfectly. We also have to point out that
the dose of NAC used in the present study was far greater
than that used in clinical practice. The reason for choosing
such a high dose is that mice and man differ notably with
FE
DC
A B
Fig. 4. Representative immunohistologic findings in aortic plaques of
control, uremic and N-acetylcysteine (NAC)-treated uremic female
apolipoprotein E-deficient (apo E−/−) mice. The collagen plaque con-
tent (Sirius red staining) in uremic placebo mice (B) was significantly
increased compared with control nonuremic mice (A) and was re-
duced by NAC (C). Nitrotyrosine protein expression (brown). Control
nonuremic mice (D). Note strong staining for nitrotyrosine in the cen-
ter of the plaque in uremic placebo mice (E). NAC treatment in uremic
mice completely prevented the observed up-regulation (F) (magnifica-
tion ×10). Abbreviations are: M, media; P, plaque; L, lumen.
respect to the rate at which they produce free radicals.
The rate of free radical generation per unit body weight
is several-fold higher in small animals, reflecting a higher
metabolic rate [35]. In addition, hypercholesterolemia
per se promotes oxidation by still unclear mechanisms
[36], and the degree of hypercholesterolemia in apoE−/−
mice far exceeds that seen in human subjects. Further-
more, it is not known whether NAC would have simi-
lar effects on atherosclerosis progression in nonuremic
subjects. Several trials showed that antioxidants did not
reduce the risk of fatal or nonfatal infarctions in an uns-
elected popoulation with established atherosclerosis [35,
37]. However, it would seem resonable that a population
under high oxidative stress such as CRF patients might
benefit the most from antioxidant intervention.
There is an increasing body of evidence in favor of
an involvement of ROS in accelerated atherosclerosis in
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CRF. Two recent reports suggested that antioxidant ther-
apy might be beneficial in reducing cardiovascular events
in this patient population [6, 7]. The present study lends
further support to the contention that NAC treatment has
a direct positive impact on uremia-enchanced atheroscle-
rosis.
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